•  
  •  
 

Indian Journal of Research in Homoeopathy

Keywords

50 Millesimal potency, Aggravation, Chi-square, Constitution, Nanoparticle

Article Type

Original Article

Abstract

Introduction: The 50 millesimal potency, is not fully utilized in our day to day practice. This retrospective study was done to reveal a new horizon for the physicians who use it occasionally and an eye opener for those who have never tried it. Aim: The aim was to evaluate the usefulness of 50 Millesimal potency of indicated medicine in the treatment of chronic diseases from a retrospective study. Materials and Methods: Cases treated with 50 Millesimal potency (LM) during January-May 2014, were screened and based on eligibility criteria, 50 cases were selected to study retrospectively. Treatment outcome was analyzed based on follow-up criteria. Data were statistically analyzed with Chi-square test in GNU PSPP Software. Results: 50 Millesimal potencies have the potential to give significant improvement (P = 0.01) in the treatment of chronic diseases. There were no cases reported with aggravation. The action of LM potency is not influenced (P = 0.97) by previously used Centesimal potency. Constitutional prescription has proved to have significant (P = 0.01) association with treatment outcome with LM potency, whereas Sector prescription (P = 0.12) does not. Irrespective of age, gender, and duration of illness, 50 Millesimal potencies act advantageously. Conclusion: The data suggest that 50 Millesimal potencies have significant beneficial effects in the treatment of chronic diseases.

Digital Object Identifier

10.4103/0974-7168.159535

Publisher

Wolters Kluwer India Pvt. Ltd.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.